Compare ALKS & JEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALKS | JEF |
|---|---|---|
| Founded | 1987 | 1968 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 10.0B |
| IPO Year | 2012 | 2016 |
| Metric | ALKS | JEF |
|---|---|---|
| Price | $48.17 | $51.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $43.43 | ★ $61.40 |
| AVG Volume (30 Days) | 1.6M | ★ 1.9M |
| Earning Date | 05-05-2026 | 03-25-2026 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | $1,475,899,000.00 | ★ $10,823,677,000.00 |
| Revenue This Year | $24.26 | $13.23 |
| Revenue Next Year | $4.47 | $10.25 |
| P/E Ratio | ★ N/A | $76.50 |
| Revenue Growth | N/A | ★ 2.93 |
| 52 Week Low | $25.17 | $35.53 |
| 52 Week High | $55.67 | $71.04 |
| Indicator | ALKS | JEF |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 36.50 |
| Support Level | $47.66 | $51.26 |
| Resistance Level | $51.25 | $54.53 |
| Average True Range (ATR) | 1.61 | 1.54 |
| MACD | -0.13 | -0.40 |
| Stochastic Oscillator | 6.63 | 0.09 |
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since the merger, Jefferies became the core of the combined business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.